Published in Cochrane Database Syst Rev on January 01, 2003
Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25
NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol (2008) 2.13
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res (2012) 1.20
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J (2004) 1.06
The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev (2013) 0.98
Drug therapy in patients with Parkinson's disease. Transl Neurodegener (2012) 0.95
Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One (2010) 0.92
Clinical aspects and management of levodopa-induced dyskinesia. Parkinsons Dis (2012) 0.83
Parkinson's disease. BMJ (2007) 0.83
Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. J Neurol (2009) 0.79
Trends in antiparkinsonian medication use in new zealand: 1995-2011. Parkinsons Dis (2014) 0.77
Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. Neuropsychiatr Dis Treat (2014) 0.77
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias. Neurobiol Dis (2016) 0.77
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord (2015) 0.75
Medication-Induced Tardive Dyskinesia: A Review and Update. Ochsner J (2017) 0.75
Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia. J Neurophysiol (2016) 0.75
An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease. Oncotarget (2017) 0.75
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med (2000) 6.21
Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance? Clin Endocrinol (Oxf) (2008) 2.15
Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain (2000) 2.11
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience (1989) 1.64
The inpatient neurology consultation service: value and cost. Clin Med (2011) 1.56
Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson's disease. Lancet (1999) 1.52
Updated guidelines for the management of Parkinson's disease. Hosp Med (2001) 1.41
A comparison of physiotherapy techniques for patients with Parkinson's disease. Cochrane Database Syst Rev (2001) 1.21
Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol (2005) 1.09
Cerebral localisation in articulatory dyspraxia. J Neurol Neurosurg Psychiatry (1992) 1.07
Occupational therapy for patients with Parkinson's disease. Cochrane Database Syst Rev (2007) 1.01
Adherence therapy for medication non-compliant patients with hypertension: a randomised controlled trial. J Hum Hypertens (2011) 1.01
Physiotherapy for patients with Parkinson's Disease: a comparison of techniques. Cochrane Database Syst Rev (2001) 0.99
Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide. Br J Pharmacol (2007) 0.95
Sensitivity of PCR in detecting monoclonal B cell proliferations. J Clin Pathol (1993) 0.92
Inherited prion disease with an alanine to valine mutation at codon 117 in the prion protein gene. Brain (1999) 0.92
Positive immunoglobulin gene rearrangement study by the polymerase chain reaction in a colonic adenocarcinoma. Am J Clin Pathol (1992) 0.92
Ventriculoperitoneal shunt procedure complicated by ureter obstruction. Case report. J Neurosurg (1983) 0.91
Surgery for Parkinson's disease: lack of reliable clinical trial evidence. J Neurol Neurosurg Psychiatry (2003) 0.91
Idiopathic intracranial hypertension associated with iron deficiency anaemia: a lesson for management. Eur Neurol (2009) 0.90
Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. Hosp Med (1998) 0.90
Clinical spectrum of neuroleptic malignant syndrome. Lancet (1988) 0.89
Non-pharmacological therapies for dysphagia in Parkinson's disease. Cochrane Database Syst Rev (2001) 0.87
Induction of chorea and dystonia in parkinsonian primates. Mov Disord (1990) 0.86
The use of complementary and alternative medicine by patients attending a UK headache clinic. Complement Ther Med (2010) 0.84
A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease. Cochrane Database Syst Rev (2001) 0.84
Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord (2003) 0.84
Brachial plexus injury as an unusual complication of coronary artery bypass graft surgery. Postgrad Med J (2003) 0.83
Amantadine in Parkinson's disease. Cochrane Database Syst Rev (2003) 0.83
Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord (1990) 0.82
Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: a randomised controlled trial. Int J Clin Pract (2014) 0.82
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci (1987) 0.82
Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2004) 0.81
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2004) 0.81
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci (1987) 0.80
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2001) 0.79
Speech and language therapy for dysarthria in Parkinson's disease. Cochrane Database Syst Rev (2001) 0.77
Silent nocardia cerebral abscesses in treated dermatomyositis. Postgrad Med J (1990) 0.76
Timing of levodopa therapy: evidence from MPTP-treated primates. Lancet (1987) 0.76
Uncertainties in the pharmacotherapy of Parkinson's disease and how to solve them. Gerontology (2002) 0.76
Ropinirole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2000) 0.76
Epidemiology of joint disorders in Parkinson's disease and their impact on health status. J Clin Neurosci (2009) 0.76
Beta-blocker therapy for tremor in Parkinson's disease. Cochrane Database Syst Rev (2003) 0.76
Ropinirole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2001) 0.75
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2001) 0.75
Retrospective diagnosis of fatal herpes simplex myelitis by immunocytochemistry and polymerase chain reaction. J Neurol Neurosurg Psychiatry (1994) 0.75
Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 0.75
Comparison of the tendon and plantar strike methods of eliciting the ankle reflex. J Neurol Neurosurg Psychiatry (2003) 0.75
Neuroleptic malignant syndrome. Lancet (1989) 0.75
[Parkinson disease]. Praxis (Bern 1994) (2001) 0.75
Cabergoline for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2001) 0.75
Ovarian hyperstimulation syndrome and benign intracranial hypertension in pregnancy after in-vitro fertilization and embryo transfer: case report. Hum Reprod (1999) 0.75
Occupational therapy for patients with Parkinson's disease. Cochrane Database Syst Rev (2001) 0.75
The mechanism by which pentagastrin stimulates gastric acid secretion. Br J Surg (1969) 0.75
Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Brain Res Mol Brain Res (1989) 0.75
Temazepam toxicity precipitated by disulfiram. Lancet (1994) 0.75
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev (2000) 0.75
Retrospective evaluation of the diagnostic accuracy of Parkinsonism in a UK community based movement disorders clinic. Parkinsonism Relat Disord (2012) 0.75